UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group

Value in health, 2012-12, Vol.15 (8), p.1108-1118

2012

Volltextzugriff (PDF)

Cost-Effectiveness of Plerixafor (PXF) for Stem Cell Mobilization in Lymphoma (NHL/HL) and Multiple Myeloma (MM) Patients in Poland

Value in health, 2013-11, Vol.16 (7), p.A384-A385

2013

Volltextzugriff (PDF)

EE489 The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

Value in health, 2022-12, Vol.25 (12), p.S151-S152

2022

Volltextzugriff (PDF)

Insulin glargine is cost-effective in treatment of patients with diabetes type-2 in whom nph insulin does not provide adequate glycaemic control – The case of poland

Value in health, 2013-05, Vol.16 (3), p.A165-A165

2013

Volltextzugriff (PDF)

Introducing the ENCePP Working Group (WG) on Health Technology Assessment (HTA): Enhancing the Generation of Additional Evidence for HTA Processes

VALUE IN HEALTH, 2013, Vol.16 (7), p.A491-A491

2013

Volltextzugriff (PDF)

PAR11 COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND

Value in health, 2007, Vol.10 (6), p.A246-A246

2007

Volltextzugriff (PDF)

PAR8 LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND:A COST-EFFECTIVENESS ANALYSIS

Value in health, 2007, Vol.10 (6), p.A245-A245

2007

Volltextzugriff (PDF)

PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

Value in health, 2009, Vol.12 (7), p.A280-A280

2009

Volltextzugriff (PDF)

PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND

Value in health, 2008, Vol.11 (6), p.A463-A463

2008

Volltextzugriff (PDF)

PCN13 COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND

Value in health, 2007, Vol.10 (3), p.A127-A127

2007

Volltextzugriff (PDF)

PCN18 THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL CHEMOTHERAPEUTIC AGENTS IN POLAND

Value in health, 2003-11, Vol.6 (6), p.738-738

2003

Volltextzugriff (PDF)

PCN32 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

Value in health, 2007, Vol.10 (3), p.A133-A133

2007

Volltextzugriff (PDF)

PCN38 COST-EFFECTIVENES ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN AS THE INDUCTION CHEMOTHERAPY OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN POLAND

Value in health, 2009, Vol.12 (3), p.A43-A43

2009

Volltextzugriff (PDF)

PCN6 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION

Value in health, 2009, Vol.12 (7), p.A257-A257

2009

Volltextzugriff (PDF)

PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

Value in health, 2008, Vol.11 (6), p.A481-A481

2008

Volltextzugriff (PDF)

PCN69 COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA

Value in health, 2010, Vol.13 (3), p.A36-A36

2010

Volltextzugriff (PDF)

PCN7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM

Value in health, 2009, Vol.12 (7), p.A257-A257

2009

Volltextzugriff (PDF)

PCN83 COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR SOLID TUMORS OR LYMPHOMAS

Value in health, 2010, Vol.13 (3), p.A39-A39

2010

Volltextzugriff (PDF)

PCN88 COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA

Value in health, 2010, Vol.13 (3), p.A40-A40

2010

Volltextzugriff (PDF)

PCV36 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND

Value in health, 2008, Vol.11 (6), p.A391-A392

2008

Volltextzugriff (PDF)

PCV4 Comparative Efficacy of Maintenance of Sinus Rhythm Versus Rate Control Strategies in the Treatment of Atrial Fibrillation – Systematic Review and Meta-Analyses

Value in health, 2011, Vol.14 (7), p.A364-A364

2011

Volltextzugriff (PDF)

PCV80 ECONOMIC ANALYSIS OF ENOXAPARIN IN COMPARISON WITH FONDAPARINUX IN THE TREATMENT OF DEEP-VEIN THROMBOSIS (DVT)

Value in health, 2010, Vol.13 (3), p.A164-A164

2010

Volltextzugriff (PDF)

PDB13 REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND: A BUDGT IMPACT ANALYSIS

Value in health, 2008, Vol.11 (6), p.A499-A499

2008

Volltextzugriff (PDF)

PDB13 THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS

Value in health, 2005-11, Vol.8 (6), p.A158-A158

2005

Volltextzugriff (PDF)

PDB27 THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND

Value in health, 2008, Vol.11 (3), p.A226-A226

2008

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieValue In Health

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Kollektion

Wiley Online Library Journals Frontfile Complete
(39)
EZB Free E-Journals
(39)
Journals@Ovid Complete
(39)
IngentaConnect Journals
(39)
Elsevier ScienceDirect Journals Complete
(39)
Applied Social Sciences Index & Abstracts (ASSIA)
(2)
MEDLINE
(2)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group

Cost-Effectiveness of Plerixafor (PXF) for Stem Cell Mobilization in Lymphoma (NHL/HL) and Multiple Myeloma (MM) Patients in Poland

EE489 The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

Insulin glargine is cost-effective in treatment of patients with diabetes type-2 in whom nph insulin does not provide adequate glycaemic control – The case of poland

Introducing the ENCePP Working Group (WG) on Health Technology Assessment (HTA): Enhancing the Generation of Additional Evidence for HTA Processes

PAR11 COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND

PAR8 LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND:A COST-EFFECTIVENESS ANALYSIS

PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND

PCN13 COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND

PCN18 THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL CHEMOTHERAPEUTIC AGENTS IN POLAND

PCN32 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

PCN38 COST-EFFECTIVENES ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN AS THE INDUCTION CHEMOTHERAPY OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN POLAND

PCN6 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION

PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

PCN69 COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA

PCN7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM

PCN83 COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR SOLID TUMORS OR LYMPHOMAS

PCN88 COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA

PCV36 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND

PCV4 Comparative Efficacy of Maintenance of Sinus Rhythm Versus Rate Control Strategies in the Treatment of Atrial Fibrillation – Systematic Review and Meta-Analyses

PCV80 ECONOMIC ANALYSIS OF ENOXAPARIN IN COMPARISON WITH FONDAPARINUX IN THE TREATMENT OF DEEP-VEIN THROMBOSIS (DVT)

PDB13 REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND: A BUDGT IMPACT ANALYSIS

PDB13 THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS

PDB27 THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND

Aktive Filter

Suchergebnisse filtern